Neurochem starts Alzhemed Phase III

Neurochem (TSE:NRM; NRMX) began a double-blind Phase III trial of its Alzhemed in 950 patients with mild to moderate Alzheimer's disease (AD). Patients in the North American trial will receive placebo...